Evidence map›Paper›PMID 12087019›Full record

Trial reportDiabetes care2002

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.

Vasilios G Athyros, Athanasios A Papageorgiou, Valasia V Athyrou, Dimokritos S Demitriadis, Athanasios G Kontopoulos

Registry-linked trialOpen access · bronzeAbstract readClinical TrialComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetes care, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04882293 (Confirmatory Study of the Efficacy and Safety of the Fixed-dose Combination Atorvastatin / Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients With Type 2 Diabetes), which is not on this map. Cited by 58 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 6 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04882293 phase3unknown statusstarted 2022, after this paper: background citation

Confirmatory Study of the Efficacy and Safety of the Fixed-dose Combination Atorvastatin / Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients With Type 2 Diabetes (T2D) and Dyslipidaemia (DLP).

Ran2022Enrolled78Registered outcomes14Posted comparisons0ConditionsDyslipidemia Associated With Type II Diabetes MellitusArmsAtorvastatin 20 mg / Fenofibrate 160 mg in fixed dose, Atorvastatin (Lipitor ®)
PMID 24603993PMID 24083205PMID 24516261other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 6 syntheses or guidelines pooled it, 260 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Treatment of lipids and type 2 diabetes.Current cardiology reports · 2004
    Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Statins-Their Effect on Lipoprotein(a) Levels.Reviews in cardiovascular medicine · 2025
    Review
  15. Review
  16. Article
  17. Risk and Benefits of Statins in Glucose Control Management of Type II Diabetes.The International journal of angiology : official publication of the International College of Angiology, Inc · 2018
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Vasilios G AthyrosLipid Out-patient Clinic, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece. athyros@med.auth.gr
Athanasios A Papageorgiou
Valasia V Athyrou
Dimokritos S Demitriadis
Athanasios G Kontopoulos
Aristotle University of Thessaloniki · GRHippocration General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study evaluated the effect of a atorvastatin-fenofibrate combination on lipid profile, in comparison to each drug alone, in patients with type 2 diabetes and combined hyperlipidemia (CHL). RESEARCH DESIGN AND

methodsA total of 120 consecutive patients, who were free of coronary artery disease (CAD) at entry, were studied for a period of 24 weeks. These patients were randomly assigned to atorvastatin (20 mg/day, n = 40), micronized fenofibrate (200 mg/day, n = 40), or a combination of both (atorvastatin 20 mg/day plus fenofibrate 200 mg/day, n = 40). The effect of treatment on LDL cholesterol, triglycerides (TGs), HDL cholesterol, apolipoprotein A-I and B, lipoprotein(a), and plasma fibrinogen (PF) was recorded. Moreover, the percentage of patients that reached the American Diabetes Association treatment goals and the estimated CAD risk status were calculated.

resultsNo patient was withdrawn from the study because of side effects. The atorvastatin-fenofibrate combination reduced total cholesterol by 37%, LDL cholesterol by 46%, TGs by 50%, and PF by 20%, whereas it increased HDL cholesterol by 22% (P < 0.0001 for all). These changes were significantly better than those of both monotherapies. Of the patients on drug combination, 97.5% reached the LDL cholesterol treatment goal of <100 mg/dl, 100% reached the desirable TG levels of <200 mg/dl, and 60% reached the optimal HDL cholesterol levels of >45 mg/dl. These rates were significantly higher than those of both monotherapies. Combined treatment reduced the 10-year probability for myocardial infarction from 21.6 to 4.2%.

conclusionsThe atorvastatin-fenofibrate combination has a highly beneficial effect on all lipid parameters and PF in patients with type 2 diabetes and CHL. It improved patients' CAD risk status significantly more than each drug alone.

Indexed as

AdultAgedAnticholesteremic AgentsApolipoproteinsAtorvastatinBlood GlucoseCholesterolCholesterol, LDLDiabetes Mellitus, Type 2Drug Therapy, CombinationFemaleFenofibrateFibrinogenHeptanoic AcidsHumansHyperlipidemiasAnticholesteremic AgentsApolipoproteinsAtorvastatinBlood GlucoseCholesterolCholesterol, LDLFenofibrateFibrinogenHeptanoic AcidsLipoprotein(a)Lipoproteins, HDLPyrrolesTriglycerides

Identifiers

PMID12087019
OpenAlexW2106340207

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.